Cure8 trial brief
Researchers are testing whether baseline fecal microbiome profiles can predict who with mild ulcerative colitis will benefit from a specific prebiotic supplement. If validated, this approach could move dietary therapy toward a more personalized strategy for symptom improvement and microbiome changes.
Adults with mild ulcerative colitis; researchers in microbiome and diet interventions; clinicians interested in personalized nutrition approaches for IBD.
This is a ClinicalTrials.gov record for a randomized, double-blind, placebo-controlled trial testing whether a specific prebiotic supplement (acacia gum, partially hydrolyzed guar gum, and resistant starch) increases butyrate and improves symptoms in adults with mild ulcerative colitis who are classified as “predicted responders” or “predicted non-responders” based on baseline fecal microbiome profiles.
The trial planned an 8-week intervention (6 g/day) with follow-up visits up to 60 weeks and listed primary and secondary outcomes including symptom score (P‑SCCAI), fecal calprotectin, stool measures, fecal short‑chain fatty acids, microbiota composition, quality of life, medication changes, and adverse events.
The record states the study was withdrawn; this listing describes the planned design and outcomes rather than trial results. It may still be useful for understanding the research question (microbiome signatures predicting dietary response) and the specific prebiotic formulation tested.
If you’re tracking microbiome-directed diet studies in UC, this trial is an example of a stratified interventional design aiming to validate a predictive microbiome signature. It does not provide efficacy data because the registry shows the study was withdrawn and no results are reported.
This entry is a trial record (planned interventional study) and does not contain study results; the registry status is WITHDRAWN, so the planned study was not completed as registered.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
